JP7398840B2 - Ａｍｐｋ抑制機能と亜鉛恒常性調節機能に基づく多発性硬化症治療用の薬学的組成物 - Google Patents

Ａｍｐｋ抑制機能と亜鉛恒常性調節機能に基づく多発性硬化症治療用の薬学的組成物 Download PDF

Info

Publication number
JP7398840B2
JP7398840B2 JP2022528544A JP2022528544A JP7398840B2 JP 7398840 B2 JP7398840 B2 JP 7398840B2 JP 2022528544 A JP2022528544 A JP 2022528544A JP 2022528544 A JP2022528544 A JP 2022528544A JP 7398840 B2 JP7398840 B2 JP 7398840B2
Authority
JP
Japan
Prior art keywords
zinc
multiple sclerosis
group
indol
eae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022528544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501814A (ja
JP2023501814A5 (https=
Inventor
キム，ヤンヒ
オム，ジェウォン
ソ，サンウォン
チェ，ボヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zincure Corp
Original Assignee
Zincure Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zincure Corp filed Critical Zincure Corp
Publication of JP2023501814A publication Critical patent/JP2023501814A/ja
Publication of JP2023501814A5 publication Critical patent/JP2023501814A5/ja
Application granted granted Critical
Publication of JP7398840B2 publication Critical patent/JP7398840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022528544A 2019-11-14 2020-11-12 Ａｍｐｋ抑制機能と亜鉛恒常性調節機能に基づく多発性硬化症治療用の薬学的組成物 Active JP7398840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190145709 2019-11-14
KR10-2019-0145709 2019-11-14
PCT/KR2020/015932 WO2021096270A1 (ko) 2019-11-14 2020-11-12 Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물

Publications (3)

Publication Number Publication Date
JP2023501814A JP2023501814A (ja) 2023-01-19
JP2023501814A5 JP2023501814A5 (https=) 2023-04-25
JP7398840B2 true JP7398840B2 (ja) 2023-12-15

Family

ID=75911395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528544A Active JP7398840B2 (ja) 2019-11-14 2020-11-12 Ａｍｐｋ抑制機能と亜鉛恒常性調節機能に基づく多発性硬化症治療用の薬学的組成物

Country Status (6)

Country Link
US (1) US12343335B2 (https=)
EP (1) EP4066832A4 (https=)
JP (1) JP7398840B2 (https=)
KR (1) KR102770734B1 (https=)
CN (1) CN114929217A (https=)
WO (1) WO2021096270A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513143A (ja) 2002-08-29 2006-04-20 アプライド リサーチ システムズ アルス ホールディング ナムローゼ フエンノートシャップ タンパク質チロシンホスファターゼ阻害剤
CN104059060A (zh) 2014-05-30 2014-09-24 西安交通大学 一种5-(1h-吲哚-3-亚甲基)-1,3-噻唑烷-4-酮类衍生物及其合成方法和应用
US20190167647A1 (en) 2016-08-09 2019-06-06 Industry Academy Cooperation Foundation Of Sejong University Pharmaceutical composition for stroke treatment based on ampk inhibition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255419A (en) * 1979-09-27 1981-03-10 Allergan Pharmaceuticals, Inc. Zinc deficiency in multiple sclerosis
GB0915892D0 (en) * 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
KR101324647B1 (ko) 2010-12-10 2013-11-01 한국과학기술연구원 다발성신경경화증의 치료 또는 예방용 조성물 및 이의 스크리닝 방법
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
US20140086839A1 (en) * 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513143A (ja) 2002-08-29 2006-04-20 アプライド リサーチ システムズ アルス ホールディング ナムローゼ フエンノートシャップ タンパク質チロシンホスファターゼ阻害剤
CN104059060A (zh) 2014-05-30 2014-09-24 西安交通大学 一种5-(1h-吲哚-3-亚甲基)-1,3-噻唑烷-4-酮类衍生物及其合成方法和应用
US20190167647A1 (en) 2016-08-09 2019-06-06 Industry Academy Cooperation Foundation Of Sejong University Pharmaceutical composition for stroke treatment based on ampk inhibition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
細胞外亜鉛とミクログリアの機能制御，Biomedical Research on Trace Elements，2017年08月02日，Vol. 28, No.3，121-126

Also Published As

Publication number Publication date
US12343335B2 (en) 2025-07-01
US20230000839A1 (en) 2023-01-05
KR102770734B1 (ko) 2025-02-21
JP2023501814A (ja) 2023-01-19
EP4066832A1 (en) 2022-10-05
CN114929217A (zh) 2022-08-19
KR20220088750A (ko) 2022-06-28
WO2021096270A1 (ko) 2021-05-20
EP4066832A4 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
US11517572B2 (en) Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid
Tong et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice
Inden et al. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson’s disease rat model
Stackman et al. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment
Culmsee et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid β‐peptide
US20200338097A1 (en) Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions
Lee et al. Hypoglycemia induces tau hyperphosphorylation
US20200338040A1 (en) Methods for treating alzheimer's disease and related disorders
JP6548738B2 (ja) 脳アミロイド血管症の予防及び治療用医薬品を製造するためのエダラボンの使用
Hung et al. The protective role of peroxisome proliferator-activated receptor-gamma in seizure and neuronal excitotoxicity
KR20120024529A (ko) 신경섬유 매듭 및 아밀로이드 베타의 축적으로부터 기인하는 진행성 인지 기능 장애의 치료용 렙틴 조성물 및 치료 방법
US20160310481A1 (en) Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
JP2021520362A (ja) 再ミエリン化を増加させるための組成物および方法
JP2021502971A (ja) リソソーム機能の改善および神経変性疾患の治療のための方法および組成物
JP6353110B2 (ja) タウ凝集阻害剤
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
JP7398840B2 (ja) Ａｍｐｋ抑制機能と亜鉛恒常性調節機能に基づく多発性硬化症治療用の薬学的組成物
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
Yu et al. The variations of Endophilin A2-FoxO3a-autophagy signal in AngⅡ-induced dopaminergic neuron injury mouse model and By Biochanin A
Tang et al. Sphingosine-1-phosphate protects against sepsis-associated encephalopathy by suppressing heparanase-mediated endothelial glycocalyx degradation
WO2025242858A1 (en) Composition for selective elimination of senescent cells
JP2023542516A (ja) アルツハイマー病の前駆フェーズにおける新規な神経保護治療ターゲットとしてのアストロサイトｔｒｐａ１チャネル抑制

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231128

R150 Certificate of patent or registration of utility model

Ref document number: 7398840

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150